Vanderbilt-Ingram Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vanderbilt-Ingram Cancer Center sits in the top decile of US sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count).
Vanderbilt-Ingram Cancer Center: 189 sponsored US clinical trials, 28 recruiting.
Vanderbilt-Ingram Cancer Center sponsors 189 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 87 completed. 7 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Vanderbilt-Ingram Cancer Center ranks in the top decile of sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
87 of 152 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
189 total, page 4 of 4
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00503997
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
NCT00651716
Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants
NCT00474604
Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
NCT00483457
Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
NCT00469937
Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol
NCT01230515
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
NCT00897793
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
NCT00503776
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT00574366
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
NCT00897650
PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca
NCT00467116
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
NCT00608517
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00425750
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT00666211
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
NCT00466505
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
NCT00466687
Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
NCT00470405
A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
NCT00483821
Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)
NCT00664105
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00343512
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00471718
Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00469898
Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
NCT00469963
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
NCT00466856
Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck Cancer
NCT00483639
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
NCT00898430
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
NCT00611715
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
NCT00512798
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
NCT00653328
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
NCT00082667
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
NCT00633750
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00416650
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
NCT00336960
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
NCT00608595
National Registry and Blood Bank of Patients With Liver Cancer
NCT00482365
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00639769
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00647218
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00006104
Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer
NCT00002519
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 51 |
| Phase 3 | 4 |
| Phase 4 | 3 |
What is open in the Vanderbilt-Ingram Cancer Center pipeline
28 recruiting of 189 indexed (15% open); 87 completed (46%).
Phase mix: 7 late (III/IV) vs 97 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vanderbilt-Ingram Cancer Center: open-pipeline peers nationwide
Peers matched on 189 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Vanderbilt-Ingram Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 189 trials (± recruiting share)
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- Arizona State University · 187 trials · 15% recruiting
- Johns Hopkins Bloomberg School of Public Health · 187 trials · 14% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- University of Rochester · 15% recruiting · 636 trials
- Loma Linda University · 15% recruiting · 237 trials
- University of Washington · 15% recruiting · 1,048 trials
Related
What to do with this Vanderbilt-Ingram Cancer Center page
189 registered trials is a research-attention snapshot, not an endorsement of Vanderbilt-Ingram Cancer Center or any single study.
- 28 of Vanderbilt-Ingram Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition Vanderbilt-Ingram Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vanderbilt-Ingram Cancer Center pipeline card: 189 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.